Cancer drug trial for lymphoma patients without key mutation pulled before start
NCT ID NCT06068881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was a phase 2 study testing the oral drug tazemetostat in adults with relapsed or refractory follicular lymphoma whose tumors lack an EZH2 gain-of-function mutation. The drug is already approved for this cancer, but researchers wanted to see how well it works in this specific group. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tazemetostat (Tazverik)
- What this could lead to
- If successful, this could provide a treatment option for people with follicular lymphoma who lack the EZH2 mutation and have few alternatives.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data is available. Tazemetostat is already approved for this cancer, but its effectiveness in this specific group remains unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a targeted drug beat radiation for early-stage lymphoma?